Cytostatic and cytotoxic effects of tyrphostin AG1296 on RMS cells

Małgorzata Lasota¹, Andrzej Klein¹, Walentyna Balwierz¹

¹Department of Pediatric Oncology and Hematology, Polish-American Institute of Pediatrics, Faculty of Medicine, Jagiellonian University Medical College, Kraków, Poland
²Department of General Biochemistry, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Kraków, Poland

Introduction

Protein tyrosine kinases (PTK) play a crucial role in the regulation of many cellular processes [1]. Tyrosine kinases are important mediators of the signalling cascade, determining key roles in diverse biological processes such as growth, differentiation, metabolism and apoptosis in response to external and internal stimuli [2]. Their activity is normally tightly controlled and regulated. Perturbation of PTK signalling by mutations and other genetic alterations results in deregulation of kinase activity and malignant transformation [3]. Dysregulation of protein kinases occurs in a variety of diseases including cancer, diabetes, and autoimmune, cardiovascular, inflammatory, and nervous disorders [4].

Though their activity is tightly regulated in normal cells, they may acquire transforming functions due to mutation(s), overexpression and autocrine/paracrine stimulation, leading to malignancy. Normally the level of cellular tyrosine kinase phosphorylation is tightly controlled by the antagonizing effect of tyrosine kinases and tyrosine phosphatases. There are several mechanisms by which tyrosine kinases might acquire transforming functions, but the ultimate result is the constitutive activation of normally controlled pathways leading to the activation of other signalling proteins and secondary messengers, which serves to hamper the regulatory functions in cellular responses such as cell division, growth and cell death. Constitutive activation of tyrosine kinases may occur by several mechanisms. Important mechanisms leading to tyrosine kinase deregulation are mutations, deletions and chromosomal translocation [2, 5].

There exists a whole group of oncogenic tyrosine kinases activated by chromosomal translocations, which are included in the fusion tyrosine kinase family due to their structure resemblance. Fusion tyrosine kinases (FTKs) such as BCR/ABL, TEL/ABL, TEL/JAK2, TEL/PDGFR, TEL/TRKC(L), and NPM/ALK arise from reciprocal chromosomal translocations and cause acute and chronic leukaemias and non-Hodgkin’s lymphoma [6]. FTKs and other oncogenic tyrosine kinases such as v-Src and HER-2/ neu activate multiple signalling pathways responsible for protection from apoptosis, induction of growth factor independent proliferation, transformation, and resistance to therapeutic drugs and to γ-radiation [6, 7].

Autocrine-paracrine stimulation serves as an important mechanism for the constitutive activation of tyrosine kinases, especially receptor tyrosine kinases. This activation loop is stimulated when a receptor tyrosine kinase is abnormally expressed or overexpressed in the presence of its associated ligand or when there is overexpression of the ligand in the presence of its cognate receptor. Autocrine/paracrine stimulation plays a role in a variety of human cancers [2, 8].

Autocrine loops involving the epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor (PDGFR), or insulin-like growth factor receptor (IGFR) have been described in many cancers [9-14]. Increased expression of EGFR is reported in many human cancers including non-small cell lung can-
cer, bladder cancer, breast cancer and glioblastoma multiforme [2]. PDGF and its receptor play an important role in lung and prostate lung cancers, renal cell carcinoma, chronic monomyelocytic leukaemia (CML) and glioblastoma [2, 15]. Co-expression of IGFR and its ligands IGF I and IGF II was reported in the pathogenesis of breast cancer, prostate cancer and small cell lung cancer [2].

Constitutive oncogenic activation in cancer cells can be blocked by selective tyrosine kinase inhibitors, which is therefore considered a promising approach for innovative genome-based therapeutics. Recent progress in determining the mechanisms by which growth factors control cell proliferation has contributed to the development of treatment strategies that target specific signal transduction pathways to control proliferative disorders. Hence low molecular weight tyrosine phosphorylation inhibitors (tyrphostins) have been proposed to be prospective anti-proliferating agents.

PDGF and its receptors are involved in a variety of diseases: cancers, atherosclerosis, balloon injury induced restenosis, pulmonary fibrosis and more. In all cases enhanced signalling of the receptor is the hallmark. In some cases, such as chronic monomyelocytic leukaemia (CML), persistent PDGF signalling is essential for the survival of the cancer cell [15]. These findings induced the research community as well as the pharmaceutical industry to develop agents that block PDGF signalling (e.g. AG17, AG370, AG1295, STI571, CT52923, SU11248 and more).

These results strongly suggest the potential role of PDGFR inhibitors in RMS cells growth regulation and viability. The aim of the work was to determine the influence of tyrphostin AG1296 (inhibitor of PDGFR tyrosine kinase) on autocrine growth of rhabdomyosarcoma RMS cells.

Materials and methods

Chemicals and reagents

Dulbecco’s modified minimal essential medium (DMEM), Hchoest No. 33258, propidium iodide and tyrosine kinase inhibitor AG1296 were purchased from Sigma (St. Louis, Mo., USA). Fetal bovine serum (FBS) was obtained from Biowest, South American Origin. Other reagents were provided by POCh (Gliwice, Poland). Stock solutions of the tyrosphostin were prepared by dissolving the compounds in dimethylsulfoxide (DMSO) to a final concentration of 10 mM and storing the resultant solutions at –20°C. DMEM/F12 (1 : 1) medium was used do dilute stock solutions to working concentrations (0.1-100 µM).

Cell culture

RMS cells were obtained from the American Type Culture Collection (ATCC) and cultured in DMEM, supplemented with 100 IU/ml penicillin and 100 mg/ml streptomycin in the presence of 10% fetal bovine serum (FBS). The cells were passaged two times per week using 0.05% trypsin solution with 0.02% EDTA in phosphate buffered saline (PBS) without Ca²⁺ and Mg²⁺.

Cell proliferation assay

Target cells were seeded on 96-well plates at concentrations of 8 x 10³ cells/well in DMEM, supplemented with 100 IU/ml penicillin and 100 mg/ml streptomycin in the presence of 10% FBS. Following 24 h of incubation, the culture medium was replaced with serum-free DMEM/F12 (1 : 1) supplemented with transferrin (5 mg/ml), sodium selenite (2 ng/ml) and albumin (0.5 mg/ml) [DMEM/F12+]. After an additional 24 h of incubation (Day 0), the medium was replaced with serum-free DMEM/F12+ medium containing tyrosine kinase inhibitor AG1296 (0.1-100 µM). The incubation was continued for the next 48 h at 37°C in humidified atmosphere. The modified crystal violet (CV) staining method [16] and the MTT tetrazolium assay (MTT) [17] were used to determine the influence of the tyrosphostin on proliferation of target cells. The absorbance was measured using a Tecan (Spectra Fluor Plus) multiscan plate recorder. Ten replicate wells were used for each experiment. The influence of tyrosine kinase inhibitors was expressed as a relative (to the controls) decrease in cell growth determined after 48 h of incubation with the investigated compounds. The calculated parameter was:

\[ G_i = \frac{A_i - A_0}{A_C - A_0} \times 100\% \]

where Gi is growth inhibition, and Ao, Ac, Ai are average values of absorbance at 540 nm (CV) or 570 nm (MTT) of the control sample at the start of the experiment (Ao), after 48 h of incubation (Ac), and after 48 h of incubation with the investigated inhibitors (Ai).

Assessment of cell viability

The differential staining method (Hoechst 33258/Pi) was used in the investigation of the effect of tyrphostin AG1296 on the viability of RMS cells [18]. The cells were seeded on 24-well plates at a density of 3 x 10³ per well in 0.8 ml DMEM with 10% FBS. Following 24 h of incubation, the culture medium was replaced with serum-free DMEM/F12+ medium. After an additional 24 h of incubation, the cells were exposed to 10-100 µM concentrations of the investigated tyrosphostin and 50 nM pacitaxel (Taxol). The experiment was carried out for 48 h and then Hoechst No. 33258 and propidium iodide were added to the final concentration of 5 µg/ml and 1 µg/ml, respectively. After 15 min, the cells were directly examined on plates with a fluorescent Olympus IMT 2 microscope. Two excitation filters were used: one allowing for excitation of both dyes, the other allowing for excitation of only PI. The Image J software was used for image processing (emerging RGB channels, enhancing contrast and sharpening) and the quantitative analysis of the processed pictures (cell counting). It allowed for estimating the fraction of dead cells (PI/DNA signal), viable cells (Hoechst 33258/DNA signal), and apoptotic cells (Hoechst 33258/DNA signal with morphological changes characteristic of last-phase apoptosis). Each experiment was repeated at least six times. Images with the number of cells exceeding approximately 100 were selected for the analysis.

Statistical analysis

The statistical analysis was performed using the Statistics 6 program. The effects of different tyrphostin concentrations on RMS cell proliferation were analysed using one way ANOVA, followed by Dunnett’s test. The Mann Whitney
U test was used to determine differences in the percentage of alive, apoptotic and necrotic cells in the control sample versus tyrphostin or paclitaxel (Taxol) treated samples. Differences were considered significant at \( p < 0.05 \). The mean ± SEM of at least ten replicates (CV) or four replicates (differential staining method) were used for statistical comparison.

**Results**

Rhabdomyosarcoma cells were exposed for 48 h to tyrosine kinase inhibitor AG1296 added at the concentration range of 0.1-100 \( \mu \text{M} \). The effect of the investigated tyrphostin determined by the CV and MTT methods is shown in Fig. 1.

The AG1296 inhibitor affects RMS cell proliferation in a dose-dependent manner at the concentration range 1-100 \( \mu \text{M} \). Both methods showed 50% inhibition of cell growth in the concentration range 5-10 \( \mu \text{M} \). Tyrophostin AG1296 caused an effect of growth inhibition (Gi) of RMS cells. The growth of the investigated cells was almost completely inhibited at concentration 25 \( \mu \text{M} \). Gi reached 93.79 ± 5.37% (determined by the CV method) and 88.91 ± 5.17% (by MTT method). At concentrations higher than 25 \( \mu \text{M} \) there was 100% inhibition of growth of these cells and a cytotoxic effect was observed.

50% inhibition of the growth of RMS cells was determined by fitting a sigmoidal model of the dose-dependent effect of the investigated tyrphostin (Fig. 2), calculated from the equation:

\[
H[\%K] = \frac{100}{1 + 10^{\log (IC_{50}-C_{inh})}} 
\]

The IC\(_{50}\) coefficient calculated from the growth inhibition curves was 7.76 ± 0.35 \( \mu \text{M} \) for AG1296. The results showed a cytostatic activity against RMS cells of the investigated tyrosine kinase inhibitor.

The investigated tyrosine kinase inhibitor was also examined for its cytotoxic potential and the ability to induce tumour cell apoptosis or necrosis. The influence of tyrophostin AG1296 on target cell viability was assessed after double staining with Hoechst 33258 and propidium iodide. Viable cells were dyed on blue, apoptotic on light-blue and necrotic cells on red. The effect of 10 \( \mu \text{M} \) concentration of tyrphostin AG1296 in comparison with the 50 nM dose of paclitaxel is shown in Fig. 3.

Apoptosis is the predominant form of cell death and occurs under a variety of physiological and pathological conditions. Apoptotic cells were clearly distinguishable by their characteristic morphology (cytoplasmic blebbing, cell shrinkage, nuclear condensation and fragmentation) (Fig. 3). Such morphological alterations were found in all investigated cell cultures; however, in the case of control cultures, they did not exceed 10% of the total cell population. The results of

**Fig. 1.** Growth inhibition of cancer cell line (RMS) by inhibitor AG1296 determined by modified crystal violet staining method and MTT test after 48 h of incubation in serum-free medium (DMEM/F12) \( \text{NS} = \text{non-significant} (p > 0.05) \) in comparison with control sample (without AG1296); * \( 0.01 < p < 0.05 \), ** \( 0.001 < p < 0.01 \)

**Fig. 2.** Dose-dependent effect of tyrphostin AG1296 on the growth of RMS cells after 48 h of incubation in serum-free DMEM/F12+ medium

**Fig. 3.** Typical picture of the cultures of RMS cells after 48 h of incubation: a) control, b) 10 \( \mu \text{M} \) AG1296 and c) 50 nM Taxol

Dark blue – viable cells; blue (with nuclear fragmentation) – apoptotic cells; red – necrotic cells.
has identified key genes and signalling pathways involved in disease pathogenesis. Several members of the receptor tyrosine kinase (RTK) family of cell surface receptors have been characterized as druggable targets for RMS. Through small molecule inhibitors, ligand-neutralizing agents, and monoclonal receptor-blocking antibodies, RTK activity can be manipulated to block oncogenic properties associated with RMS [20].

Rhabdomyosarcoma (RMS) is the most frequent childhood cancer originating from skeletal muscle, and patient survival is poor in the case of metastatic disease. New targeted therapeutics are critically needed [19]. Over the past two decades, research into the molecular mechanisms of RMS has identified key genes and signalling pathways involved in disease pathogenesis. Several members of the receptor tyrosine kinase (RTK) family of cell surface receptors have been characterized as druggable targets for RMS. Through small molecule inhibitors, ligand-neutralizing agents, and monoclonal receptor-blocking antibodies, RTK activity can be manipulated to block oncogenic properties associated with RMS [20].

The role of tyrosine kinases in cancer molecular pathogenesis is immense and recently kinases have come into vogue as potential anticancer drug targets, as a result of a couple of anticancer drugs that are on the market. The complexity and the number of tyrosine kinases have greatly increased with the sequencing effort of the Human Genome Project, thus providing more opportunities for drug discovery. Recent understanding of the molecular pathophysiology of cancer has highlighted that many tyrosine kinases are found upstream or downstream of epidemiologically relevant oncogenes or tumour suppressors, in particular the receptor tyrosine kinases [2].

Several types of PDGF antagonists have been described, including antibodies or DNA aptamers against ligands or the extracellular part of the receptors, as well as low molecular weight receptor kinase inhibitors (e.g. imatinib, sunitinib and sorafenib) [21-27]. The latter also inhibited the growth of RMS cells (IC_{50} = 5 µM) [28]. Imatinib represents a kinase inhibitor for which there is already some clinical experience [21, 29]. Another PDGF receptor antagonist that, despite having a broad specificity, shows a tolerable toxicity profile and promising results from phase I clinical trials is SU11248 [21]. The mechanism of action of AG1296, a potent and specific inhibitor of the platelet-derived growth factor (PDGF) receptor tyrosine kinase, has been investigated [30-32].

We have determined whether blockade of PDGFR signalling pathways inhibits autocrine growth and viability of RMS cells in vitro. In RMS cells, AG1296 inhibited proliferation in a dose-dependent manner with an IC_{50} value of 7.76 ±0.35 µM. Our results indicate that each of the investigated tyrphostins at concentrations > 25 µM is able to completely inhibit RMS autocrine cell growth. The obtained results were very similar, regardless of the method of growth evaluation which was applied (CV, MTT). At concentrations higher than 40 µM, the amount of cells dropped below the initial density, which indicated the cytotoxic effect.

The differential staining method showed that the investigated tyrphostin, used at concentration > 10 µM, had direct cytotoxicity on the RMS cell line. After the 48-hour incubation the percentage of viable cells decreased significantly with the increase of tyrophostin concentration and equaled 75.9% (20 µM concentration), 69.4% (40 µM concentration), 58.7% (80 µM concentration) and 22.6% (100 µM concentration). It turned out that the kinase inhibitor PDGFR stimulates mainly the apoptotic process of the investigated cells. The amount of apoptotic cells increased from 18.5% for the control to 75.5% for the concentration of tyrphostin AG1296 to 75.5% for the concentration of tyrphostin AG1296. With the incubation time prolonged to 72 h resulted in a dramatic decrease of viability of cells to about 40% (results not shown).

Discussion

The results of these experiments indicate that autocrine growth of RMS cells is regulated by at least one autocrine loop, involving PDGF and its receptor (PDGFR). The fact that tyrphostin AG1296 is able to complete inhibition of RMS cell growth in vitro gives a chance for providing a new group of antitumor drugs, which may be more effective than the medicines used so far.
References

1. Kemp BE, Pearson RB. Protein kinase recognition sequence motifs. Trends Biochem Sci 1990; 15: 342-6.
2. Manash PK, Anup MK. Tyrosine kinase – Role and significance in Cancer. Int J Med Sci 2004; 1: 101-15.
3. Blume-Jensen P, Hunter T. Oncogenic kinase signalling, Nature 2001; 411: 355-65.
4. Roskoski Jr R. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biomem Biophys Res Commun 2004; 319: 1-11.
5. Bertram JS. The molecular biology of cancer. Mol Aspects Med 2002; 22: 4189.
6. Slupianek A, Hoser G, Majsterek I, Bronisz A, Malecki M, Blasiak J, Fishel R, Skorski T. Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G2/M phase, and protection from apoptosis. Mol Cell Biol 2002; 22: 3046-55.
7. Hochhaus A, Kreil S, Corbin A, et al. Roots of clinical resistance to STI-571 cancer therapy. Science 2001; 293: 2163.
8. Kulik G, Klippel A, Weber M. Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol Cell Biol 1997; 17: 1595-606.
9. Berlanga-Acosta J, Gavilondo-Cowley J, del Barco-Herrera D, et al. Epidermal growth factor (EGF) and platelet-derived growth factor (PDGF) as tissue healing agents: clarifying concerns about their possible role in malignant transformation and tumor progression. J Carcinogene Mutagene 2011; 1: 115.
10. Rojas A, Liu G, Coleman I, et al. IL-6 promotes prostate tumorigenesis and progression through autocrine type-2 receptor activation. Cancer 2004; 95: 2753-62.
11. Martins AS, Olmos D, Missiaglia E, Shipley J. Targeting the insulin-like growth factor pathway in rhabdomyosarcomas: rationale and future perspectives. Sarcoma 2011; 2011: 209736.
12. Ciaraldi TP, Sasaoka T. Review on the in vitro interaction of insulin glargine with the insulin/insulin-like growth factor system: potential implications for metabolic and mitogenic activities. Horm Metab Res 2011; 43: 1-10.
13. Ostman A. PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev 2004; 15: 275-86.
14. Ranson M, Hammond LA, Ferry D, et al. ZD1839, a selective oral eri- dermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 2002; 20: 2240-50.
15. Leviutzki A. PDGF receptor kinase inhibitors for the treatment of PDGF driven diseases. Cytokine Growth Factor Rev 2004; 15: 229-35.
16. Gillies RJ, Didier N, Denton M. Determination of cell number in monolayer cultures. Anal Biochem 1986; 159: 109-13.
17. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63.
18. Darzynkiewicz Z, Li X, Gong J. Assays of cell viability: discrimination of cells dying by apoptosis. Methods Cell Biol 1994; 41: 15-38.
19. Barti-Jahasz H, Mihalik R, Nagy K, Griessi G, Dominici M, Petak L. Bone marrow derived mesenchymal stem/stromal cells transduced with full length human TRAIL repress the growth of rhabdomyosarcoma cells in vitro. Haematologica 2011; 96: e21-2.
20. Crosse LE, Linardic CM. Receptor tyrosine kinases as therapeutic targets in rhabdomyosarcoma. Sarcoma 2011; 2011: 756982.
21. Pietras K, Sjöblom T, Rubin K, Heldin CH, Ostman A. PDGF receptors as cancer drug targets. Cancer Cell 2003; 3: 439-43.
22. Yoshitani K, Honoki K, Morishita T, Kido A, Miyaychi Y, Mii Y, Takakura Y. Growth inhibition of rat osteosarcoma and malignant fibrous histiocytoma cells by tyrosine kinase inhibitor STI571. In Vivo 2003; 17: 255-8.
23. McGary EC, Weaver K, Mills L, Doucet M, Lewis V, Lev DC, Fidler II, Bar-Eli M. Inhibition of platelet-derived growth factor mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571. Clin Cancer Res 2002; 8: 3584-91.
24. Slater G, Shipley J. Clinical relevance of molecular genetics to paediatric sarcomas. J Clin Pathol 2007; 60: 1187-94.
25. Armistead PM, Salganick J, Roh JS, et al. Expression of receptor tyrosine kinases and apoptotic molecules in rhabdomyosarcoma: correlation with overall survival in 105 patients. Cancer 2007; 110: 2293-303.
26. Kreuter M, Paulusse M, Boeckeler J, et al. Clinical significance of Vascular Endothelial Growth Factor-A expression in Ewing’s sarcoma. Eur J Cancer 2006; 42: 1904-11.
27. Give MF, Tsuchida R, Eichler-Jonsson C, Das B, Baruchel S, Malkin D. Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid. Oncogene 2005; 24: 8025-37.
28. Maruwwe W, D’Arcy P, Folin A, et al. Sorafenib inhibits tumor growth and vascularization of rhabdomyosarcoma cells by blocking IGF-IR-mediated signaling. Oncotargets Ther 2008; 1: 67-78.
29. Capdeville R, Buchdunger E, Zimmermann J, Matter A, Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002; 1: 493-502.
30. Kovalenko M, Rönnstrand L, Heldin CH, Loubtchenkov M, Gazit A, Leviutzki A, Böhmer FD. Phosphorylation site-specific inhibition of platelet-derived growth factor beta-receptor autophosphorylation by the receptor blocking typhostin AG1296. Biochemistry 1997; 36: 6260-9.
31. Ahn HY, Hadizadeh KR, Seul C, Yon YP, Vetter H, Sachnidsi A. Epigallocatechin-3 gallate selectively inhibits the PDGF-BB-induced intracellular signaling transduction pathway in vascular smooth muscle cells and inhibits transformation of sis-transfected NIH 3T3 fibroblasts and human glioblastoma cells (A172). Mol Biol Cell 1999; 10: 1093-104.
32. Kumar RN, Ha HH, Radhakrishan R, Dhanasekaran DN. Transactivation of platelet-derived growth factor receptor alpha by the GTPase-deficient activated mutant of Galphal2. Mol Cell Biol 2006; 26: 50-62.

Address for correspondence
Małgorzata Lasota
Klinika Onkologii i Hematologii Dziecięcej
Polsko-Amerykański Instytut Pediatrii
ul. Wielicka 265
30-663 Kraków
e-mail: mlagorzata.lasota@uj.edu.pl

Submitted: 3.06.2011
Accepted: 18.01.2012